ZofranLegal.com reports that lawsuits alleging that anti-nausea drug Zofran can cause birth defects to form in babies exposed to it while growing in utero have been consolidated to form MDL number 2657 in Boston, Massachusetts. These lawsuits recently surpassed 200 in number, and plaintiffs have watched presiding Judge F. Dennis Saylor IV appoint 5 attorneys to lead the plaintiffs’ steering committee.
Two of the appointed attorneys are connected to ZofranLegal.com and have worked for several months with lead attorney Michael Monheit to assist with the process of filing Zofran birth defect lawsuits against manufacturer and pharmaceutical conglomerate GlaxoSmithKline.
About a month ago, Judge Saylor also announced his initial five official court orders for the cases involved. The orders effectively set up a master list for court filings to follow, and indicate that lawyers would have the option of calling, rather than appearing in person, to participate in status conferences, the latest of which was held on December 16th. The orders also address the defendant in the cases, pharmaceutical giant GlaxoSmithKline, indicating that at this time, they are not required to answer all filed complaints. Answers will not have to be provided, in fact, until a more streamlined process has been established by the court.
Plaintiffs involved in the MDL all synonymously allege that Zofran exposure to fetuses can cause a range of birth defects to develop, including clubfoot, tetralogy of fallot, transposition of the greater vessels, cleft lip and palate, respiratory defects, kidney defects, atrial septal defect, and ventricular septal defect. Several of the lawsuits note that the birth defects were fatal, ending the lives of the infants born with them.
Attorneys appointed to lead the Zofran MDL are: Elizabeth Graham, Esq., Robert K. Jenner, Esq., Kimberly Dougherty, Esq., Kimberly Barone Baden, Esq., and Tobias Millrood, Esq. These attorneys bring many years of professional experience and legal knowledge to the table.
As the MDL cases await trial, many expect that others will continue to be filed, especially due to the popularity of Zofran as a morning sickness drug. Zofran was prescribed “off-label” to an estimated 1 million pregnant women within the last year. These prescriptions are considered “off-label” due to the fact that Zofran has never been FDA-approved to treat morning sickness in pregnant women, or tested for safety on this consumer group.
The attorneys at Monheit Law are attempting to ensure that all families negatively affected by Zofran can have the ability to fully investigate their legal rights. Affected mothers and children may be entitled to legal action and compensation. Those who were prescribed Zofran while pregnant and who subsequently gave birth to an infant with defects are being offered free legal consultations from Monheit Law.
To request additional information on Zofran lawsuits or to ask questions, contact Michael Monheit, Esq. by calling (877) 620-8411.
###
Contact ZofranLegal.com:
Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046
